---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-385293"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2026-09-08T20:41:28+00:00"
generated_at: "2026-09-08T20:43:09.951579+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "low"
source: SEC EDGAR
---

# Inhibikase updates September 2026 corporate presentation; no new financial or pipeline details disclosed

## Summary
- Furnished updated corporate presentation dated September 2026 for investor, analyst, and other meetings.
- Reported September 8, 2026; signed by CEO Mark Iwicki.
- Available exhibit text contains only a standard disclaimer; no specific financials, pipeline data, or milestones included in filing excerpt.
- Presentation furnished under Regulation FD; common stock trades as IKT on Nasdaq.

## SEC filing metadata
- accession: 0001193125-26-385293
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2026-09-08T20:41:28+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312526385293/0001193125-26-385293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312526385293/d152999d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-385293
- JSON: https://secwatch.observer/filing/0001193125-26-385293.json
- Plain text: https://secwatch.observer/filing/0001193125-26-385293.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.